Stahl A, Lepore D, Fielder A, et al. - In this randomized, open-label, superiority multicentre, three-arm, parallel-group trial conducted in 87 neonatal and ophthalmic centers in 26 countries of 225 infants with birth weight less than 1,500 g who met criteria for treatment for retinopathy, researchers assessed the efficiency and safety of intravitreal ranibizumab vs laser therapy in treatment of retinopathy of prematurity (ROP). Individuals were randomized evenly (1:1:1) to receive a single bilateral intravitreal dose of ranibizumab 0·2 mg or ranibizumab 0·1 mg, or laser therapy. In the treatment of ROP, compared with laser therapy and with an acceptable 24-week safety profile, it was discovered that ranibizumab 0·2 mg could be better than laser therapy, with less hostile ocular outcomes.